Jamie Christensen's insider trading at Mirati Therapeutics
SEC Form 4 filings for Christensen Jamie,

Insider trading of Jamie Christensen, a SVP, Chief Science Officer at MRTX Mirati Therapeutics, Inc.

Most recently Jamie Christensen sold 14,725 shares worth $338,527.75 on 11 January 2018.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2018-01-11 Jamie Christensen
SVP, Chief Science Officer
SVP, Chief Science Officer Sale 14,725 $22.99 $338,527.75
2018-01-11
2,877 SEC insider form 4
2017-11-16 Jamie Christensen
SVP, Chief Science Officer
SVP, Chief Science Officer Sale 10,275 $18.00 $184,950.00
2017-11-16
2,395 SEC insider form 4
2017-11-02 Jamie Christensen
SVP, Chief Science Officer
SVP, Chief Science Officer Option exercise 7,499 $5.50 $41,244.50
2017-11-02
10,169 SEC insider form 4
2017-10-04 Jamie Christensen
SVP, Chief Science Officer
SVP, Chief Science Officer Option exercise 4,000 $8.50 $34,000.00
2017-10-04
6,670 SEC insider form 4
2017-09-15 Jamie Christensen
SVP, Chief Science Officer
SVP, Chief Science Officer Sale 770 $12.00 $9,240.00
2017-09-15
2,670 SEC insider form 4
Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company??s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

  • Mirati Therapeutics, Inc., 9393 Towne Centre Drive, San Diego 92121, United States
  • mirati.com
  • 858-332-3410
Messenger